What is your approach to adjuvant endocrine therapy in hormone receptor positive male breast cancers?
Is there any role for aromatase inhibitors? What duration of therapy do you recommend?
Answer from: Medical Oncologist at Community Practice
Tamoxifen should be the standard adjuvant endocrine therapy for ER+ breast cancer in men. There has been talk intermittently about aromatase inhibitor (AI) use as alternative endocrine therapy, and I would not recommend the use of AIs in this setting. Data is limited, with the one study comparing ou...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree that tamoxifen remains the standard adjuvant therapy (including extended therapy for higher risk cases), and if tamoxifen is contraindicated, GnRH agonist/antagonist plus aromatase inhibitor as recommended by the ASCO Guidelines for male breast cancer (Hassett et al., PMID 32058842).